Page 73 - CIBER-BBN2016-ENG

Most relevant scientific articles
• Terra X., Gómez D., García-Lorenzo J., Flores J.C., Figuerola E., Mora J. et al. External validation of sTWEAK as a prognostic noninvasive biomarker for head and neck squamous cell carcinoma. Head and Neck. 2016.
• Pavón M.A., Arroyo-Solera I., Céspedes M.V., Casanova I., León X., Mangues R. uPA/uPAR and SERPINE1 in head and neck cancer: Role in tumor resistance, metastasis, prognosis and therapy. Oncotarget. 2016;7(35):57351-57366.
• Vázquez E., Mangues R., Villaverde A. Functional recruitment for drug delivery through protein-based nanotechnologies. Nanomedicine. 2016;11(11):1333-1336.
• Céspedes M.V., Fernández Y., Unzueta U., Mendoza R., Seras-Franzoso J., Sánchez-Chardi A. et al. Bacterial mimetics of endocrine secretory granules as immobilized in vivo depots for functional protein drugs. Scientific Reports. 2016;6.
• Céspedes M.V., Guillén M.J., López-Casas P.P., Sarno F., Gallardo A., Álamo P. et al. Lurbinectedin induces depletion of tumor-associated macrophages, an essential component of its in vivo synergism with gemcitabine, in pancreatic adenocarcinoma mouse models. DMM Disease Models and Mechanisms. 2016;9(12):1461-1471.
Highlights
During this year, we have enhanced the focus of the group towards developing and evaluating the nanoconjugate proposed in the CIBER-BBN intramural project, Nanomets, for which we have count
with active funding from a FIS Project and an Integrated Project of Excellence of the ISCIII, a Marató TV3 Project and two Transference Projects, one from AGAUR and another that covers the support of the the Advisory Board of the EC-funded Consortium ENATRANS. We have also continued contract work with
two Spanish Pharmaceutical Companies, one of them receiving funding from a Retos MINECO project.
One Miguel Servet, and two Sara Borrell Researchers, and Clinical Specialists, in Surgery or Medical Oncology, that are doing their PhD, are currently working in the laboratory. Two new PhD students were incorporated to the group after getting contracts for resaerch trainning from ISCIII and AGAUR. Two doctoral dissertations directed by group members have been defended. The PI of the group was invited speaker
in three International Conferences on Molecular Imaging, Personalized Cancer Medicine or Targeted
Drug Delivery. He was also appointed to the French Institut National du Cancer Translational Research Scientific Committee. Together with Villaverde’s group, our group has demonstrated specific-uptake of the Nanomets protein nanococarrier and the drug-nanoparticle conjugate to metastasis stem cells, opening a new approach to achieve selective antimetastatic effect. We are now setting the knowledge base that will allow the constuction of protein-based nanomedicines that incorporate the requiered functional domains to achieved targeted drug delivery to specific cell types. Our group has also achieved selective killing of tumor associated macrophages of the stroma using a marketed drug and demonstrated its sinergistic antitumor effect when combined with a genotoxic drug that directly kill cancer cells. We established new collaborations with Celine Gongora of the Montpellier Instute National de la Sante (France).
BBN
Research Groups 73